Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4· 4 million participants
…, OH Franco, G Frontera, T Furusawa, Z Gaciong - The lancet, 2016 - thelancet.com
Background One of the global targets for non-communicable diseases is to halt, by 2025,
the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to …
the rise in the age-standardised adult prevalence of diabetes at its 2010 levels. We aimed to …
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the …
…, TR Pedersen, JG Park, GM De Ferrari, ZA Gaciong… - The Lancet, 2017 - thelancet.com
Background LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular
disease. How much one should or safely can lower this risk factor remains debated. We …
disease. How much one should or safely can lower this risk factor remains debated. We …
Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses
Z Gaciong, M Siński, J Lewandowski - Current hypertension reports, 2013 - Springer
Stroke is the second most common cause of death worldwide and of adult disability, but in
the near future the global burden of cerebrovascular diseases will rise due to ageing and …
the near future the global burden of cerebrovascular diseases will rise due to ageing and …
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice
…, P Frost, V Dreisbach, J Blenis, Z Gaciong… - Proceedings of the …, 2001 - pnas.org
PTEN phosphatase acts as a tumor suppressor by negatively regulating the phosphoinositide
3-kinase (PI3K) signaling pathway. It is unclear which downstream components of this …
3-kinase (PI3K) signaling pathway. It is unclear which downstream components of this …
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
…, A Januszewicz, A Tykarski, J Walczewska, Z Gaciong… - The Lancet, 2022 - thelancet.com
Background Resistant hypertension is associated with increased cardiovascular risk. The
endothelin pathway has been implicated in the pathogenesis of hypertension, but it is currently …
endothelin pathway has been implicated in the pathogenesis of hypertension, but it is currently …
Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey
…, J Stokwiszewski, Z Gaciong… - Polish Heart …, 2016 - journals.viamedica.pl
Background: Poland represents a country of high cardiovascular (CV) risk. The association
between lipid abnormalities and increased CV risk is well established. Therefore, it is …
between lipid abnormalities and increased CV risk is well established. Therefore, it is …
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20
…, M Wasik, K Warzocha, M Sinski, Z Gaciong… - PLoS …, 2008 - journals.plos.org
Background Rituximab is used in the treatment of CD20 + B cell lymphomas and other B cell
lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations …
lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations …
[HTML][HTML] Lack of PTEN sequesters CHK1 and initiates genetic instability
…, L Memeo, M Mansukhani, VVVS Murty, Z Gaciong… - Cancer cell, 2005 - cell.com
Pten −/− cells display a partially defective checkpoint in response to ionizing radiation (IR).
The checkpoint defect was traced to the ability of AKT to phosphorylate CHK1 at serine 280, …
The checkpoint defect was traced to the ability of AKT to phosphorylate CHK1 at serine 280, …
Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE
…, KA Im, SA Murphy, GM De Ferrari, ZA Gaciong… - Circulation, 2023 - ahajournals.org
Background: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for
atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with …
atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with …
Cardiovascular effects mediated by hmmr and cd44
K Jaskuła, M Sacharczuk, Z Gaciong… - Mediators of …, 2021 - Wiley Online Library
Cardiovascular disease (CVD) is the leading cause of death worldwide. The most dangerous
life‐threatening symptoms of CVD are myocardial infarction and stroke. The causes of CVD …
life‐threatening symptoms of CVD are myocardial infarction and stroke. The causes of CVD …